Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative biotherapeutics for cancer treatment. On December 12, 2019, Alphamab Oncology was listed on the Main Board of Hong Kong Stock Exchange, with the stock code:9966. With multiple in-house proprietary platforms of bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/immunology with more than 20 phase II-III clinical trials ongoing, and we are striving to develop next generation and best-in-class medicines to address unmet medical needs and accessibility globally.
To combat the complexity of cancer, the ongoing development of cancer therapy requires multi-modality treatments. Our technology platforms, such as bispecific and mixed-antibody platforms, have empowered us to use innovative technology to integrate multiple distinct biotherapeutics into one molecule or one CMC process, with great potential to improve the efficacy and safety beyond current treatments. Meanwhile, treatment cost could be drastically reduced to address the accessibility issue. At Alphamab Oncology, developing effective next generation biologics for cancer treatment is our passion and commitment.
Alphamab team takes great pride in our track record of excellence in the development and manufacturing of innovative and complex biologics.
Our current pilot plant has supported the IND approval and clinical supply of four of our pipeline products undergoing more than 20 clinical trials around the world.
Our state-of-the-art cGMP biologics manufacturing site is under rapid expansion to support commercialization in the global markets.